Lr-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats

Diabetologia

Volumn 46, Issue 8, 2003, Pages 1140-1152

  Figarola, J L ^a   Scott, S ^a   Loera, S ^a   Tessler, C ^a   Chu, P ^a   Weiss, L ^a   Hardy, J ^a   Rahbar, S ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

AGE inhibitor; Carbonyl stress; Collagen; Diabetes; Glycation; Metal chelation; Nephropathy; Oxidative stress; Proteinuria; Reactive carbonyl species

Indexed keywords

3 NITROTYROSINE; ADVANCED GLYCATION END PRODUCT; ALBUMIN; AMINOGUANIDINE; ASCORBIC ACID; CARBONYL DERIVATIVE; CHELATING AGENT; COLLAGEN; COPPER ION; CREATININE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; IMMUNOGLOBULIN G; ISOBUTYRIC ACID DERIVATIVE; LR 90; METHYLENE BIS[4,4' (2 CHLOROPHENYLUREIDOPHENOXYISOBUTYRIC ACID)]; PAPAIN; PEPSIN A; PYRIDOXAMINE; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL INFILTRATION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG MECHANISM; GLOMERULOSCLEROSIS; GLOMERULUS; GLUCOSE BLOOD LEVEL; GLYCATION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY CORTEX; KIDNEY TUBULE DISORDER; MALE; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN CROSS LINKING; RAT; STREPTOZOCIN DIABETES;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; BUTYRATES; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMOGLOBIN A, GLYCOSYLATED; KIDNEY; KIDNEY FUNCTION TESTS; MALE; RATS; RATS, SPRAGUE-DAWLEY; REFERENCE VALUES;

EID: 0041877502     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-003-1162-0     Document Type: Article

References (77)

1. Bucala R, Cerami A (1992) Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv Pharmacol 23: 1-34
2. Brownlee M (1995) Advanced protein glycosylation in diabetes and aging. Ann Rev Med 46:223-234
3. Singh R, Barden A, Mori T, Beilin L (2001) Advanced glycation end-products: a review. Diabetologia 44: 129-146
4. Schleicher ED, Bierhaus A, Haring HU, Nawroth, Lehmann R (2001) Chemistry and pathobiology of advanced glycation end products. Contrib Nephrol 131:1-9
5. Vlassara H, Palace MR (2002) Diabetes and advanced glycation endproducts. J Intern Med 251:87-101
6. Miyata T, Kurokawa K, De Strihou CVY (2000) Advanced glycation and lipoxidation end products: role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism
7. Baynes JW, Thorpe SR (1999) Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48:1-9
8. Wolff SP, Bascal ZA, Hunt JV (1989) Autoxidative glycosylation: free radicals and glycation theory. Prog Clin Biol Res 304:259-275
9. Wolff SP, Jiang, ZY, Hunt JV (1991) Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Radic Biol and Med 10:339-352
10. Loske C, Gerdemann A, Schepl et al. (2000) Transition metal-mediated glycoxidation accelerates cross-linking of beta-amyloid peptide. Eur J Biochem 267:4171-4178
11. Scivittaro V, Ganz MB, Weiss MF (2000) AGEs induce oxidative stress and activate protein kinase C-beta (II) in neonatal mesangial cells. Am J Physiol Renal Physiol 278:F676-F683
12. Suzuki D, Miyata T, Saotome N et al. (1999) Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. J Am Soc Nephrol 10:822-832
13. Miyata T, Wada Y, Cai Z et al. (1997). Implications of an increased oxidative stress in the formation of advanced glycation endproducts in patients with end stage renal failure. Kidney Int 51:1170-1181
14. Friedman EA (1999) Advanced glycation end-prodcuts in diabetic nephropathy. Nephron Dial Transplant 14 [Suppl. 3]:1-9
15. Mogensen CE (1999) Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas. Diabetologia 42:263-285
16. Lehmann R, Schleicher ED (2000) Molecular mechanism of diabetic nephropathy. Clin Chim Acta 297:135-144
17. Yamamoto Y, Kato I, Doi T et al. (2001) Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 108:261-268
18. Makita Z, Radoff S, Rayfield EJ et al. (1991) Advanced glycation endproducts in patients with diabetic nephropathy. N Engl J Med 325:836-842
19. Vlassara H, Fuh H, Makita Z, Li YM, Steffes M (1994) Advanced glycation end-products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 91:11704-11708
20. Bendayan M (1998) Immunocytochemical detection of advanced glycated end products in rat renal tissue as a function of age and diabetes. Kidney Int 54:438-447
21. Imai N, Nishi S, Suzuki Y et al. (1997) Histological localization of advanced glycosylation end products in the progression of diabetic nephropathy. Nephron 76:153-160
22. Horie K, Miyata T, Maeda K et al. (1997) Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. J Clin Invest 100:2995-3004
23. Heidland A, Sebekova K, Schinzel R (2001) Advanced glycation end products and the progressive course of renal disease. Am J Kidney Dis 38 [4 Suppl 1]:S100-S1006
24. Aronson D (2002) Potential role of advanced glycosylation end products in promoting restenosis in diabetes and renal failure. Med Hypotheses 59:297-301
25. Bailey AJ, Paul RG, Knott L (1998) Mechanisms of maturation and ageing of collagen. Mech Ageing Dev 106:1-56
26. Dukic-Stefanovic S, Schinzel R, Riederer P, Munich G (2001) AGEs in the brain: AGE-inhibitors as neuroprotective and anti-dementia drugs. Biogerontology 2:19-34
27. Rahbar S, Figarola JL (2002) Inhibitors and breakers of advanced glycation endproducts. Curr Med Chem - Immunol Endocrin Metabol 2:174-186
28. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A (1986) Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232:1629-1632
29. Hammes HP, Martin S, Federin K, Geisen K, Brownlee M (1991) Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 88:11555-11558
30. Bonnefont-Rousselot D (2001) Antioxidant and anti-AGE therapeutics: evaluation and perspectives. J Soc Biol 195:391-398
31. Booth AA, Khalifah RG, Hudson BG (1996) Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine. Biochem Biophys Res Commun. 220:113-119
32. Suzuki YJ, Tsuchiya M, Packer L (1992) Lipoate prevents glucose-induced protein modifications. Free Radic Res Commun 173:211-217
33. Onorato JM, Jenkins AJ, Thorpe SR, Baynes JW (2000) Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions: mechanism of action of pyridoxamine. J Biol Chem 275:21177-21184
34. Ruggiero-Lopez D, Lecomte M, Moinet G, Patereau G, Lagarde M, Wiernsperger N (1999) Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced glycation end product formation. Biochem Pharmacol 58:1765-1773
35. Nakamura S, Makita Z, Ishikawa S et al. (1997) Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 46:895-899
36. Forbes JM, Soulis T, Thallas V et al. (2001) Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia 44:108-114
37. Ninomiya T, Tsutsumi S, Kawaguchi M (2001) EF655, a novel AGE production inhibitor, prevents progression of diabetic nephrophaty in STZ-induced diabetic rats. American Diabetes Association 61st Scientific Session, Philadelphia, PA (Abstract No 724-P)
38. Vasan S, Zhang X, Zhang, XI et al.(1996) An agent cleaving glucose-derived protein cross-links in vitro and in vivo. Nature 382:275-278
39. Vaitkevicius PV, Lane M, Spurgeon H et al. (2000) A cross-link breaker has sustained effects on arterial and ventricular properties of older rhesus monkey. Proc Natl Acad Sci USA 98:1171-1175
40. Rahbar S, Yernini K, Scott S, Gonzales N, Lalezari I (1999) Novel inhibitors of glycation endproducts. Biochem Biophys Res Commun 262:651-656
41. Rahbar S, Yerneni K, Scott S, Gonzales N, Lalezari I (2000) Novel inhibitors of advanced glycation endproducts (Part II). Mol Cell Biol Res Comm 3:360-366
42. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G (1991). Retardation of aminoguanidine of development of albuminuria, mesangial expansion and tissue fluorescence in streptozotocin-induced diabetic rats. Diabetes 40:1328-1334
43. Degenhardt TP, Alderson NL, Arrington DD et al. (2002) Pyridoxamine inhibits early renal disease and dyslipidemia in streptozotocin-diabetic rats. Kidney Int 61:939-950
44. Al-Abed Y, Kapurniotu A, Bucala R (1999) Advanced glycation end products: detection and reversal. Methods Enzymol 309:152-172
45. Kochakian M, Manjula BN, Egan JJ (1996) Chronic dosing with aminoguanidine and novel advanced glycosylation end product-formation inhibitors ameliorates cross-linking of tail tendon collagen in STZ-induced diabetic rats. Diabetes 45:1694-1700
46. Stefek M, Gajdosik A, Gajdosikova A, Krizanova L (2000) p-Dimethyl aminobenzaldehyde-reactive substances in tail tendon collagen of streptozotocin-diabetic rats: temporal relation to biomechanical properties and advanced glycation endproduct (AGE)-related fluorescence. Biochim Biophys Acta 1502:398-404
47. Creemers LB, Jansen DC, van Veen-Reurings A, van den Bos T, Everts V (1997) Microassay for the assessment of low levels of hydroxyproline. Biotechniques 22:656-658
48. Verzijl N, DeGroot J, Oldehinkel E et al. (2000) Age-related accumulation of Maillard reaction products in human articular cartilage collagen. Biochem J 350:381-38
49. Wilkinson-Berka JL, Kelly D J, Koerner SM et al. (2002) ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2) 27 rat. Diabetes 51:3283-3289
50. Forbes JM, Cooper ME, Thallas V et al. (2002) Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 51:3274-3282
51. Price DL, Rhett PM, Thorpe SR, Baynes JW (2001) Chelating activity of advanced glycation end-products inhibitors. J Biol Chem 276:48967-48972
52. Voziyan PA, Metz TO, Baynes JW, Hudson BG (2002) A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation. J Biol Chem 277:3397-3403
53. Lalezari I, Rahbar S, Lalezari P, Fermi G, Perutz MF (1988) LR16, a compound with potent effects on the oxygen affinity of hemoglobin, on blood cholesterol, and on low density lipoprotein. Proc Natl Acad Sci USA 85:6117-6121
54. Lyons T, Jenkins AJ (1997) Glycation, oxidation and lipoxidation in the development of the complications of diabetes mellitus: a 'carbonyl stress' hypothesis. Diabetes Rev 5:365-391
55. Thornalley PJ, Langborg A, Minhas HS (1999) Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 344:109-116
56. Miyata T, Saito A, Kurokawa K, van Ypersele de Strihou C (2001) Advanced glycation and lipoxidation end products: reactive carbonyl compounds-related uraemic toxicity. Nephrol Dial Transplant 16 [Suppl 4]:8-11
57. Lo TW, Selwood T, Thornalley PJ (1994) The reaction of methylglyoxal with aminoguanidine under physiological conditions and prevention of methylglyoxal binding to plasma proteins. Biochem Pharmacol 48:1865-70
58. Thornalley PJ, Yurek-George A, Argirov OK (2000) Kinetics and mechanism of the reaction of aminoguanidine with the alpha-oxoaldehydes glyoxal, methylglyoxal, and 3-deoxyglucosone under physiological conditions. Biochem Pharmacol 60:55-65
59. Nagaraj RH, Sarkay P, Mally A, Biemel KM, Lederer MO, Padayatti PS (2002) Effects of pyridoxamine on chemical modifications of proteins by carbonyls in diabetic rats: characterization of a major product from the reaction of pyridoxamine with metholglyoxal. Arch Biochem Biophys 402:110-119
60. Kislinger T, Fu C, Huber B et al. (1999) N(epsilon)-(carboxymethyl) lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 274:31740-31749
61. Morcos M, Sayed AA, Bierhaus A et al. (2002) Activation of tubular epithelial cells in diabetic nephropathy. Diabetes 51:3532-3544
62. Boulanger E, Wautier MP, Wautier JL et al. (2002) AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression. Kidney Int 61:148-156
63. Basta G, Lazzerini G, Massaro M et al. (2002) Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 105:816-822
64. Thuraisingham RC, Nott CA, Dodd SM, Yaqoob MM (2000) Increased nitrotyrosine staining in kidneys from patients with diabetic nephropathy. Kidney Int 57:968-972
65. Beckman JS, Koppenol WH (1996) Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 271:C1424-C1437
66. Reiter CD, Teng RJ, Beckman JS (2000) Superoxide reacts with nitric oxide to nitrate tyrosine at physiological pH via peroxynitrite. J Biol Chem 275:32460-32466
67. Sakurai T, Tsuchiya S (1988) Superoxide production from nonenzymatically glycated protein. FEBS Lett 236:406-410
68. Yim HS, Kang SO, Hah YC, Chock PB, Yim MB (1995) Free radicals generated during the glycation reaction of amino acids by methylglyoxal. A model study of protein-cross-linked free radicals. J Biol Chem 270:28228-28233
69. Ortwerth BJ, James H, Simpson G, Linetsky M (1998) The generation of superoxide anions in glycation reactions with sugars, osones, and 3-deoxyosones. Biochem Biophys Res Commun 245:161-165
70. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL (2001) Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 280:E685-E694
71. Sajithal GB, Pandarinathan C, Chadrakasan G (1999) An in vitro study on the role of metal catalyzed oxidation in glycation and cross-linking of collagen. Mol Cell Biol 194:257-263
72. Qian M, Liu M, Eaton JW (1998) Transition metals bind to glycated proteins forming redox active "glycochelates": implications for the pathogenesis of certain diabetic complications. Biochem Biophys Res Commun 250:385-389
73. Saxena AK, Saxena P, Wu X, Obrenovich M, Weiss MF, Monnier VM (1999) Protein aging by carboxymethylation of lysines generates sites for divalent metal and redox active copper binding: relevance to diseases of glycoxidative stress. Biochem Biophys Res Commun 260:332-338
74. Yim MB, Yim HS, Lee C, Kang SO, Chock PB (2001) Protein glycation: creation of catalytic sites for free radical generation. Ann NY Acad Sci 928:48-53
75. Litchfield JE, Thorpe SR, Baynes JW (1999) Oxygen is not required for the browning and cross-linking of protein by pentoses: relevance to Maillard reactions in vivo. Int J Biochem Cell Biol 1999 31:1297-1305
76. Glomb MA, Monnier VM (1995) Mechanism of protein modification by glyoxal and glycoaldehyde, reactive intermediates of the Maillard reaction. J Biol Chem 270:10017-10026
77. Khalifah RG, Chen Y, Price DL, Booth AA (2002) Mechanism of inhibition of advanced glycation endproducts by Pyridorin™, a novel therapeutic for diabetic complications. Diabetologia 45 [Suppl 2]:A1222 (Abstract)